Daniel Zips

List of Publications by Year in Descending Order

127 papers	3,240 citations	29 h-index	52 g-index
138 ext. papers	4,132 ext. citations	3.6 avg, IF	5.01 L-index

#	Paper	IF	Citations
127	Clinical evaluation of autonomous, unsupervised planning integrated in MR-guided radiotherapy for prostate cancer.. *Radiotherapy and Oncology*, **2022**, 168, 229-233	5.3	0
126	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG.. *Radiotherapy and Oncology*, **2022**,	5.3	2
125	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [F]FMISO PET/CT.. *Radiotherapy and Oncology*, **2022**,	5.3	3
124	Simulation CT-based radiomics for prediction of response after neoadjuvant chemo-radiotherapy in patients with locally advanced rectal cancer.. *Radiation Oncology*, **2022**, 17, 84	4.2	2
123	Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. *Strahlentherapie Und Onkologie*, **2021**, 1	4.3	2
122	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. *European Urology Oncology*, **2021**,	6.7	3
121	Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). *Strahlentherapie Und Onkologie*, **2021**, 1	4.3	0
120	Salvage-Radiation Therapy and Regional Hyperthermia for Biochemically Recurrent Prostate Cancer after Radical Prostatectomy (Results of the Planned Interim Analysis). *Cancers*, **2021**, 13,	6.6	2
119	Resistance of Hypoxic Cells to Ionizing Radiation Is Mediated in Part via Hypoxia-Induced Quiescence. *Cells*, **2021**, 10,	7.9	2
118	Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI. *Cancers*, **2021**, 13,	6.6	1
117	Radiotherapy in nodal oligorecurrent prostate cancer. *Strahlentherapie Und Onkologie*, **2021**, 197, 575-580	4.3	4
116	Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors. *International Journal of Radiation Oncology Biology Physics*, **2021**, 111, 1072-1087	4	1
115	H2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture. *Radiotherapy and Oncology*, **2021**, 159, 119-125	5.3	0
114	Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. *Radiotherapy and Oncology*, **2021**, 159, 155-160	5.3	3
113	First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer. *Radiotherapy and Oncology*, **2021**, 159, 197-201	5.3	8
112	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. *Radiotherapy and Oncology*, **2021**, 159, 146-154	5.3	11
111	Automatic 3D Monte-Carlo-based secondary dose calculation for online verification of 1.5 T magnetic resonance imaging guided radiotherapy. *Physics and Imaging in Radiation Oncology*, **2021**, 19, 6-12	3.1	3

110	Value of PET imaging for radiation therapy. *Nuklearmedizin - NuclearMedicine*, **2021**, 60, 326-343	1.8	0
109	Value of PET imaging for radiation therapy. *Strahlentherapie Und Onkologie*, **2021**, 197, 1-23	4.3	1
108	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. *Pharmacogenomics Journal*, **2021**, 21, 37-46	3.5	2
107	Quality of life and fatigue before and after radiotherapy in breast cancer patients. *Strahlentherapie Und Onkologie*, **2021**, 197, 281-287	4.3	7
106	1.5 T MR-linac planning study to compare two different strategies of rectal boost irradiation. *Clinical and Translational Radiation Oncology*, **2021**, 26, 86-91	4.6	4
105	Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation. *International Journal of Radiation Oncology Biology Physics*, **2021**	4	12
104	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. *Radiotherapy and Oncology*, **2021**, 155, 204-211	5.3	1
103	Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 567-580	4	6
102	On the probability of lymph node negativity in pN0-staged prostate cancer-a theoretically derived rule of thumb for adjuvant needs. *Strahlentherapie Und Onkologie*, **2021**, 1	4.3	
101	Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation. *Strahlentherapie Und Onkologie*, **2021**, 1	4.3	
100	An Activity Tracker-Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials). *JMIR Research Protocols*, **2021**, 10, e28524	2	1
99	A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling - Rationale and first in human. *Radiotherapy and Oncology*, **2021**, 164, 37-42	5.3	1
98	Image guidance in radiation therapy for better cure of cancer. *Molecular Oncology*, **2020**, 14, 1470-1491	7.9	21
97	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. *Radiotherapy and Oncology*, **2020**, 149, 189-196	5.3	19
96	Against Repurposing Methadone for Glioblastoma Therapy. *Biomolecules*, **2020**, 10,	5.9	5
95	PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. *Strahlentherapie Und Onkologie*, **2020**, 196, 542-551	4.3	4
94	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. *Journal of Molecular Diagnostics*, **2020**, 22, 801-810	5.1	1
93	MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients. *Cancers*, **2020**, 12,	6.6	7

92	Automatic VMAT planning for post-operative prostate cancer cases using particle swarm optimization: A proof of concept study. *Physica Medica*, **2020**, 69, 101-109	2.7	6
91	Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and analysis of electron return and stream effects. *Radiotherapy and Oncology*, **2020**, 145, 30-35	5.3	27
90	Depatux-M and temozolomide in advanced high-grade glioma. *Neuro-Oncology Advances*, **2020**, 2, vdaa063	6.9	1
89	Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers. *Cancers*, **2020**, 12,	6.6	5
88	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. *Scientific Reports*, **2020**, 10, 15625	4.9	11
87	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. *Physics and Imaging in Radiation Oncology*, **2020**, 15, 52-59	3.1	2
86	Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy. *Radiotherapy and Oncology*, **2020**, 151, 182-189	5.3	12
85	Quality assurance of IMRT treatment plans for a 1.5 T MR-linac using a 2D ionization chamber array and a static solid phantom. *Physics in Medicine and Biology*, **2020**, 65, 16NT01	3.8	8
84	A multi-institution study: comparison of the heating patterns of five different MR-guided deep hyperthermia systems using an anthropomorphic phantom. *International Journal of Hyperthermia*, **2020**, 37, 1103-1115	3.7	2
83	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. *Cancers*, **2020**, 12,	6.6	11
82	Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human Glioblastoma Cells. *Cancers*, **2019**, 11,	6.6	24
81	Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	14
80	Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. *Strahlentherapie Und Onkologie*, **2019**, 195, 771-779	4.3	23
79	Organ Preservation in Rectal Cancer: The PatientsSPerspective. *Frontiers in Oncology*, **2019**, 9, 318	5.3	16
78	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic F-FMISO PET for Head and Neck Cancer Radiotherapy. *Journal of Nuclear Medicine*, **2019**, 60, 1698-1704	8.9	22
77	Intention-to-Treat Analysis of Ga-PSMA and C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. *Journal of Nuclear Medicine*, **2019**, 60, 1359-1365	8.9	18
76	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. *Radiotherapy and Oncology*, **2019**, 135, 43-50	5.3	13
75	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. *Clinical and Translational Radiation Oncology*, **2019**, 15, 108-112	4.6	6

74	Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 137-143	4	4
73	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. *European Journal of Cancer*, **2019**, 110, 11-20	7.5	33
72	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. *Radiotherapy and Oncology*, **2019**, 130, 10-17	5.3	32
71	Quantitative, Multi-institutional Evaluation of MR Thermometry Accuracy for Deep-Pelvic MR-Hyperthermia Systems Operating in Multi-vendor MR-systems Using a New Anthropomorphic Phantom. *Cancers*, **2019**, 11,	6.6	15
70	Electronic Patient-Reported Outcome Measures in Radiation Oncology: Initial Experience After Workflow Implementation. *JMIR MHealth and UHealth*, **2019**, 7, e12345	5.5	15
69	Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients. *Nuklearmedizin - NuclearMedicine*, **2019**, 58, 93-100	1.8	1
68	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. *Clinical Cancer Research*, **2019**, 25, 1505-1516	12.9	35
67	Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. *Research in Microbiology*, **2019**, 170, 74-79	4	24
66	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. *Radiotherapy and Oncology*, **2019**, 130, 97-103	5.3	9
65	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. *Cancer Immunology, Immunotherapy*, **2018**, 67, 653-662	7.4	4
64	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. *Radiotherapy and Oncology*, **2018**, 127, 27-35	5.3	12
63	Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. *Strahlentherapie Und Onkologie*, **2018**, 194, 719-726	4.3	7
62	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. *Radiotherapy and Oncology*, **2018**, 126, 125-131	5.3	20
61	Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas. *International Journal of Hyperthermia*, **2018**, 34, 980-987	3.7	4
60	Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. *Strahlentherapie Und Onkologie*, **2018**, 194, 985-990	4.3	4
59	Prospective data registration and clinical trials for particle therapy in Europe. *Radiotherapy and Oncology*, **2018**, 128, 9-13	5.3	14
58	Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients. *Radiotherapy and Oncology*, **2018**, 128, 485-491	5.3	20
57	Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. *Radiotherapy and Oncology*, **2018**, 129, 575-581	5.3	11

56	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *International Journal of Cancer*, **2018**, 142, 1911-1925	7.5	32
55	Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	12
54	Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. *Zeitschrift Fur Medizinische Physik*, **2017**, 27, 21-30	7.6	23
53	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. *Radiotherapy and Oncology*, **2017**, 122, 437-444	5.3	8
52	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. *Radiotherapy and Oncology*, **2017**, 124, 526-532	5.3	84
51	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects. *OncoImmunology*, **2017**, 6, e1323161	7.2	29
50	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. *Oncologist*, **2017**, 22, 570-575	5.7	18
49	Distortion correction of diffusion-weighted magnetic resonance imaging of the head and neck in radiotherapy position. *Acta Oncologica*, **2017**, 56, 1659-1663	3.2	7
48	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. *Radiotherapy and Oncology*, **2017**, 124, 533-540	5.3	90
47	Ex vivo H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. *Radiotherapy and Oncology*, **2017**, 124, 386-394	5.3	12
46	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. *Acta Oncologica*, **2017**, 56, 1571-1576	3.2	17
45	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. *Clinical and Translational Radiation Oncology*, **2017**, 5, 28-36	4.6	14
44	Cell-line dependent effects of hypoxia prior to irradiation in squamous cell carcinoma lines. *Clinical and Translational Radiation Oncology*, **2017**, 5, 12-19	4.6	10
43	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. *Clinical and Translational Radiation Oncology*, **2017**, 7, 36-42	4.6	9
42	TRPM8 is required for survival and radioresistance of glioblastoma cells. *Oncotarget*, **2017**, 8, 95896-95913	33	27
41	Conservative surgery with combined high dose rate brachytherapy for patients suffering from genitourinary and perianal rhabdomyosarcoma. *Radiotherapy and Oncology*, **2016**, 121, 262-267	5.3	22
40	Long-term local control and survival after preoperative radiochemotherapy in combination with deep regional hyperthermia in locally advanced rectal cancer. *International Journal of Hyperthermia*, **2016**, 32, 187-92	3.7	18
39	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. *Clinical Cancer Research*, **2016**, 22, 2639-49	12.9	88

38	Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 263-71	4	4
37	Radiation oncology in the era of precision medicine. *Nature Reviews Cancer*, **2016**, 16, 234-49	31.3	438
36	BK K+ channel blockade inhibits radiation-induced migration/brain infiltration of glioblastoma cells. *Oncotarget*, **2016**, 7, 14259-78	3.3	41
35	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. *Cancer Immunology, Immunotherapy*, **2016**, 65, 1003-13	7.4	20
34	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Radiotherapy and Oncology*, **2016**, 121, 364-373	5.3	80
33	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. *Radiotherapy and Oncology*, **2016**, 121, 447-452	5.3	8
32	Chronic graft-versus-host-disease in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. *Journal of Autoimmunity*, **2015**, 62, 55-66	15.5	29
31	H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. *Radiotherapy and Oncology*, **2015**, 116, 473-9	5.3	30
30	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. *Acta Oncologica*, **2015**, 54, 1355-63	3.2	45
29	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. *Acta Oncologica*, **2015**, 54, 1364-9	3.2	18
28	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. *Acta Oncologica*, **2015**, 54, 1658-64	3.2	26
27	Residual H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. *Radiotherapy and Oncology*, **2015**, 116, 480-5	5.3	29
26	Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial. *Radiation Oncology*, **2015**, 10, 138	4.2	8
25	Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells. *Molecular Cancer Research*, **2015**, 13, 1283-95	6.6	31
24	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 1165-1174	4	74
23	Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. *Radiotherapy and Oncology*, **2014**, 111, 81-7	5.3	32
22	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. *Radiotherapy and Oncology*, **2014**, 110, 362-9	5.3	45
21	Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 159-66	4	18

20	Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. *Radiotherapy and Oncology*, **2014**, 113, 303-9	5.3	62
19	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Radiotherapy and Oncology*, **2014**, 113, 317-23	5.3	100
18	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. *Radiation Oncology*, **2014**, 9, 261	4.2	9
17	Place of proton radiotherapy in future radiotherapy practice. *Seminars in Radiation Oncology*, **2013**, 23, 149-53	5.5	9
16	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. *Radiotherapy and Oncology*, **2012**, 102, 444-9	5.3	21
15	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. *Radiotherapy and Oncology*, **2012**, 105, 21-8	5.3	229
14	Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1205-13	4	53
13	Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. *Radiotherapy and Oncology*, **2010**, 96, 116-22	5.3	70
12	Cancer stem cells and radiotherapy. *International Journal of Radiation Biology*, **2009**, 85, 391-402	2.9	65
11	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. *Radiotherapy and Oncology*, **2009**, 92, 405-10	5.3	19
10	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. *Journal of Pharmacy and Pharmacology*, **2008**, 60, 1019-28	4.8	25
9	Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. *Strahlentherapie Und Onkologie*, **2007**, 183, 256-64	4.3	62
8	Experimental evaluation of functional imaging for radiotherapy. *Strahlentherapie Und Onkologie*, **2007**, 183 Spec No 2, 41-2	4.3	6
7	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. *Radiotherapy and Oncology*, **2007**, 83, 304-10	5.3	126
6	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. *Radiotherapy and Oncology*, **2006**, 80, 112-22	5.3	64
5	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. *Radiotherapy and Oncology*, **2006**, 81, 122-9	5.3	91
4	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. *Radiotherapy and Oncology*, **2005**, 74, 331-6	5.3	19
3	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. *Radiotherapy and Oncology*, **2005**, 76, 151-6	5.3	24

2	Selection of genetically distinct, rapidly proliferating clones does not contribute to repopulation during fractionated irradiation in FaDu squamous cell carcinoma. *Radiation Research*, **2003**, 160, 257-62	3.1	1
1	Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. *Journal of Histochemistry and Cytochemistry*, **2002**, 50, 197-204	3.4	58